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ABSTRACT
The relationship between adherence to highly active antiretroviral therapy (HAART) and RNA-HIV viral
load outcomes has been extensively shown. Although there are different procedures for assessing treatment
adherence, there is no ideal method. We present the SERAD (Self-Reported Adherence) questionnaire, a qual-
itative and quantitative self-reported instrument designed to provide an easier adherence measurement. We
also compared the questionnaire to three other methods to evaluate adherence to HAART regimens in HIV-
infected patients. Two prospective, observational, longitudinal studies were developed: a single-center pilot
study followed by a multicenter study. A total of 530 HIV-infected outpatients was prospectively included, 66
in the pilot study and 464 in the multicenter study. Four methods were used to study adherence to HAART
regimens: the SERAD questionnaire, pill count, electronic monitoring, and plasma drug monitoring. Pear-
son’s correlations and Bland and Altman’s method were developed. The SERAD questionnaire showed good
feasibility and significant validity. Adequate levels of agreement between methods were observed, particularly
when adherence was high. Differences increased as adherence fell. Moreover, the questionnaire was completed
correctly, the interviewers did not report uncovered aspects, and the information was collected easily. Our
results suggest that the SERAD questionnaire is a feasible and useful instrument for assessing adherence to
HAART regimens in HIV-infected patients, and makes it possible to obtain reliable qualitative and quanti-
tative information related to treatment adherence.
INTRODUCTION
ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY(HAART) has been extensively related to RNA-HIV viral
load outcomes and this has confirmed the strong relationship
between both issues.1–5 For this reason, an optimal knowledge
of adherence to antiretroviral treatment appears to be relevant
for clinical decisions such as HAART simplification or inten-
sification, or interrupting or delaying treatment.6 Moreover, re-
liable adherence-related information may help clinicians to as-
certain the difficulties encountered in taking the medication
adequately.7
Despite of the need for a rigorous assessment of HAART
adherence, a “gold standard” has not yet been found.8 Hitherto,
the most commonly used methods to evaluate HAART adher-
ence have been pill count, plasma drug monitoring, electronic
monitoring, and patient self-reporting. However, although some
studies have used these different assessment methods, not much
information is available with respect to comparisons among
them.7
The most usual, feasible, and less expensive way to assess
HAART adherence has been patient self-reporting. Neverthe-
less, this method has been criticized for methodological rea-
sons.9 Its validity may be limited by the type of questions used,
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question style, or the time setting in which the question is asked.
Similarly, self-reported adherence is further characterized by
the need for optimal psychometric properties. And though some
questionnaires to assess self-reported HAART adherence have
been proposed, the qualitative and quantitative information pro-
vided by them has been limited.9 For these reasons, there is a
need to find self-report instruments with precise accuracy for
antiretroviral therapy adherence assessment.
In this study we developed a standardized self-reported ques-
tionnaire, the SERAD (Self-Reported Adherence) question-
naire, which was designed to provide significant qualitative and
quantitative information related to HAART adherence. Its fea-
sibility, validity, and usefulness were studied in a pilot and mul-
ticenter study and, in addition, the application of the SERAD
was compared to three other relevant adherence methods: pill
count, electronic monitoring, and plasma drug monitoring.
MATERIALS AND METHODS
Patients
A total of 11 Spanish hospitals participated in the investiga-
tion (see Acknowledgments). HIV-infected outpatients aged
18 years old and taking a HAART combination were invited
to participate in the study. HAART combination was defined
as an antiretroviral treatment including two nucleoside or nu-
cleotide reverse transcriptase inhibitors  one nonnucleoside
reverse transcriptase inhibitor, or two nucleoside or nucleotide
reverse transcriptase inhibitors  one or more protease inhibi-
tor  one fusion inhibitor, or one nonnucleoside reverse tran-
scriptase inhibitor  one protease inhibitor. Patients were in-
formed of the purpose and procedures of the investigation, and
those who agreed to participate were recruited. All participants
provided written informed consent.
Study design
Two prospective, observational, comparative studies were de-
signed, consisting of a pilot study followed by a multicenter
study. The local ethics committee approved both study protocols.
Pilot study. A preliminary study was conducted to test the
feasibility of the subsequent multicenter protocol. Only patients
from the HIV Unit of the Germans Trias i Pujol University Hos-
pital (Barcelona, Spain) took part in this first single-center
study. Research subjects were followed up for 2 months and
assessed at visits at week 0 (baseline evaluation), week 4 (month
1), and week 8 (month 2). Sociodemographic, clinical, and psy-
chological variables were collected. Four methods were used to
study individual adherence: the SERAD questionnaire, pill
count, electronic monitoring, and plasma drug monitoring.
Multicenter study. Following the completion of the pilot
study and the analysis of the results, a second protocol was de-
veloped. This consisted of a multicenter study that maintained
the first study design. The only difference was the inclusion of
a new follow-up visit at week 12 (month 3), which was estab-
lished to offer the possibility of covering a longer period of
time to assess adherence. The 11 aforementioned HIV units par-
ticipated.
Medical and psychological assessment
The baseline evaluation included the following demographic
and clinical variables: age, gender, HIV infection route, current
consumption of toxic substances, time since HIV diagnosis,
current CD4 cell count and percentage, viral load, current
HAART and usual schedule, weeks on current treatment, and
antiretroviral treatment history. The information was collected
from patients’ medical records, reviewed, and completed at each
clinical visit. At the baseline interview, perceived social sup-
port for HIV infection and perceived capacity to follow treat-
ment (self-efficacy) were measured on a 100-mm visual ana-
logue scale (VAS).10 An instrument previously used in HIV
populations, the Beck Depression Inventory,11 was applied to
assess depression at the baseline visit. The 16PF-5 Inventory12
was used during the first month of follow-up. This tool is one
of the most commonly used personality assessment methods,
and was completed by patients to control a possible bias in the
responses provided by subjects to fulfill the interviewer’s ex-
pectations.13 The three-style response indices provided by this
instrument, impression management (IM), infrequency (IN),
and acquiescence (AQ) scales, were added as variables to be
controlled in data statistical analyses.
Adherence assessment
SERAD questionnaire. Since hitherto there has been no one
reliable way of measuring HAART adherence, we decided to
create an easy, fast, and comfortable instrument that also pro-
vided reliable qualitative and quantitative information in a sim-
ple way.
The SERAD (Self-Reported Adherence) questionnaire14 was
originally developed in Spanish, although it has now been 
translated into English (all versions are available at
www.flsida.org/serad). The Spanish version was used in the
SERAD study.
This tool was designed to be an interviewer-administered
questionnaire to ensure greater validity of the data obtained.
Most of the questions in the questionnaire were open, focusing
on obtaining quantitative answers. A SERAD usage guide14 was
created to facilitate the administration by the clinician.
Three main parts were considered in the formulation of the
SERAD. The initial part collected information on the patient’s
medication posology. This part was regarded as initial and ba-
sic, and more specifically included the medication prescribed,
the schedule to be followed, the number of dosage units pre-
scribed, and the number of daily doses. The second part dealt
with the adherence data. Unlike other self-reported methods of
adherence assessment, the SERAD provided for two types of
indexes. One was based on the number of times the patient
failed to take the medication (adherence percentage) and the
other one on the times the patient failed to observe the intake
conditions (intake conditions observed percentage). Thus, the
questionnaire made it possible to assess the number of times
the patient did not take the medication, and the compliance with
the time conditions related to the treatment, another particularly
important factor in the clinical setting.
The time-specific contexts covered by the questionnaire re-
ferred to the last week, the last month, and the last 3 months.
The possibility of covering three time contexts was a major ad-
vantage envisaged from the outset of the design. These times
VALIDATION OF THE SERAD ADHERENCE QUESTIONNAIRE 1167
were chosen to provide structured and sufficiently representa-
tive information in terms of time. The measurement of 1 day
prior to the application of the questionnaire was ruled out as it
was deemed to be rather unrepresentative. On the other hand,
some studies use measurements pertaining to 3 or 4 days be-
fore the questionnaire,10,15,16 although we considered that it was
easier for the patient to remember 7 days, which is one week,
rather than 4. Moreover, because some studies had shown good
results with these three time settings,17 the decision was finally
taken to use these three measurements.
The reasons for nonadherence were also recorded whenever
noncompliant behavior was mentioned because of the evident
clinical importance. They were coded in 13 items chosen from
the most frequently reported ones in clinical practice.18 This
was one of the main questions addressed because of the evi-
dent clinical importance of knowing why patients fail to follow
treatment properly.
The third part of the design included the totals of the calcu-
lations and the final results. The percentages of adherence were
calculated on the basis of the following formula: (total number
of dosage units prescribed  total number of times re-
ported)/(total number of dosage units prescribed)  100. And
the percentages with regard to the reasons for nonadherence
were calculated as follows: (total number of reasons reported 
total number of one concrete reason reported)/(total number of
reasons reported)  100. In the end, the SERAD made it pos-
sible to calculate the following outputs:
1. Percentage of adherence with regard to the doses missed dur-
ing the last week.
2. Percentage of reasons for nonadherence during the last week.
3. Percentage of adherence with regard to the times that intake
conditions were not observed during the last week.
4. Percentage of reasons for intake conditions not observed dur-
ing the last week.
5. Percentage of adherence with regard to the doses missed dur-
ing the last month.
6. Percentage of reasons for nonadherence during the last
month.
7. Percentage of adherence with regard to the times that intake
conditions were not observed during the last month.
8. Percentage of reasons for intake conditions not observed dur-
ing the last month.
9. Percentage of adherence with regard to the doses missed dur-
ing the last 3 months.
From the outset, our aim was to generate a single-sheet ques-
tionnaire in a comfortable format. Finally, the questionnaire
comprised a single sheet, and a computerized data base was cre-
ated where the results were calculated automatically.
To test its feasibility, the time to complete the questionnaire
was recorded and possible mistakes were also considered. The
latter were defined as any information recorded on the ques-
tionnaire that would render the correction process impossible.
The correction process consisted of the calculation of the ad-
herence percentages as well as the calculation of the rest of the
quantitative information provided by the SERAD. At the end
of the pilot and multicenter study the investigators were ques-
tioned concerning the difficulty of completing the question-
naire and possible relevant suggestions to improve data col-
lection. The SERAD was applied at week 4, 8 (pilot and mul-
ticenter study), and 12 (multicenter study) of the patient 
follow-up.
Pill count. After baseline visit, patients collected their
HAART regimen from the pharmacy hospital service, where
the number of dosage units dispensed was recorded. Patients
were instructed to return only the surplus medication collected
for the month at the next visit. This medication was recorded
again. It was assumed that patients consumed the medication
that was not returned. However, subjects reporting the use of
prior medication, or medication not returned by mistake or for-
getfulness, were not included in the evaluation. On the basis of
number of dosage units returned, an adherence percentage was
calculated with regard to the doses missed during the last month.
The following formula was applied: (total number of dosage
units collected  total number of dosage units returned)/(total
number of dosage units collected)  100. This adherence as-
sessment method was applied at the same visits as the SERAD.
Electronic monitoring. Electronic drug exposure monitors
(eDEM, AARDEX Ltd., Zug, Switzerland; www.aardex.ch)
were used. Due to logistics and cost, only 10% of patients in
the multicenter study participated. The recruitment of patients
was conducted according to a computer-generated random-
number table. The subjects selected were offered the possibil-
ity of training in the use of electronic monitoring. If they de-
clined, another patient was assigned and proposed with regard
to the randomization table. Patients who accepted were pro-
vided with an electronic drug exposure monitor cap bottle for
one of their antiretroviral drugs. Each drug assigned in the bot-
tles was selected with regard to a previously randomized list of
antiretroviral drugs, established according to the criterion of the
pharmacists of the hospital pharmacy service. The drugs were
selected particularly on the basis of dosage units that were eas-
iest to store in this type of container. The software incorporated
in the cap bottles (provided by AARDEX Ltd.) reported the
number of days monitored, the number of doses taken, adher-
ence percentage, percentage of days on which the doses pre-
scribed were taken correctly, and the percentage of prescribed
doses taken on schedule (intake conditions observed percent-
age). The time range considered was 2 h before and after the
ingested dose. Patients were specifically instructed to open the
electronic monitor cap bottle only when they took the medica-
tion, and if for any reason they opened the bottle off-schedule
they were to record this and provide the information at the fol-
lowing visit. Patients were provided with a refilled bottle at
baseline, week 4, and week 8.
Plasma drug monitoring. NNRTI and PI concentrations in
plasma were assessed in the first 200 patients who were con-
secutively included in the study. Logistics and cost determined
this proportion of patients. In an attempt to avoid modifying
the usual adherence to antiretroviral therapy, subjects were not
informed that drug concentrations were going to be measured
until blood sampling. Blood samples were collected in potas-
sium and ethylenediaminetetraacetic acid (EDTA)-containing
10-ml tubes. Plasma was isolated by centrifugation (4000 rpm
for 15 min) and stored at 80°C until analysis. Drug concen-
trations were determined by high-performance liquid chro-
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matography (HPLC) according to a validated method.19 Patients
harboring drug concentrations lower than 0.01 mg/liter were
considered to be nonadherent to antiretroviral therapy.
Data analysis
Analyses to establish the psychometric properties of the
SERAD questionnaire were developed.
Feasibility considered qualitative and quantitative aspects:
time to complete the questionnaire, recorded mistakes, under-
standing of the interviewer’s instructions, simplicity of the data
collected, aspects that could be simplified, and aspects not ad-
dressed in the questionnaire.
Validity was regarded as the agreement between the four ad-
herence assessment methods throughout the follow-up. Pear-
son’s correlations were developed to study this point. However,
since the Pearson correlation is known to underestimate the
level of agreement, a graph analysis was used. This consisted
of Bland and Altman’s method, which compared agreement be-
tween measures depending on different levels of adherence
showed.20 This method made it possible to obtain agreement
between two measures by means of a graph considering the
mean of the measures and the difference between them. In the
graph, points near 0 indicated a high agreement between mea-
sures, while points far from 0 indicated disagreement. Since
none of the methods could be considered as a “gold standard,”
all four methods were compared: SERAD questionnaire, pill
count, electronic monitoring, and plasma drug monitoring. Al-
though one of the greatest advantages of SERAD was the pos-
sibility of using different adherence measures, only four of them
were used in this study. Doses missed during the last week (1)
and the last month (5) and intake conditions not respected dur-
ing the last week (3) and last month (7) were regarded as the
most significant adherences measures. Therefore, only these
were used for the data analysis. This was because SERAD made
it possible to find new adherence measures, although this was
not a primary endpoint of the study. And because SERAD was
compared with the other three adherence methods to test its fea-
sibility, validity, and usefulness, they did not provide the new
outcomes obtained by SERAD.
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FIG. 1. Comparisons of adherence measures in pilot study by Bland and Altman’s method. (A) Agreement between electronic
monitoring and SERAD in last month adherence measure (n  38). (B) Agreement between electronic monitoring and SERAD
in last month intake conditions measure (n  38). (C) Agreement between pill count and SERAD in last month adherence mea-
sure (n  41). (D) Agreement between pill count and electronic monitoring in last month adherence measure (n  37).
A complementary analysis was performed to convert quan-
titative adherence methods into qualitative binomial measures.
The 95% adherence was taken as the cutoff point considering
the clinical criteria established by Paterson et al.1 Thus, non-
compliant subjects were those with levels of adherence 95%,
whereas those with levels of adherence 95% were regarded
as compliant. The qualitative transformation of these adher-
ence measures was used to assess agreement with plasma drug
levels.
Since it was thought that differences among adherence meth-
ods might appear, although not only associated with adherence
outcomes, a logistic regression analysis was performed to con-
trol the possible existence of concrete profiles on patients’ re-
sponses. Moreover, to study this, patients with a 	5% differ-
ence between methods were analyzed by logistic regression.
The following variables were included in the analysis: partici-
pant center, age, gender, HIV infection route, current con-
sumption of toxic substances, years since HIV diagnosis, cur-
rent CD4 cell count and percentage, current HAART and usual
schedule, perceived social support, perceived capacity to fol-
low treatment (self-efficacy), depression, and the three response
style indices of the 16PF-5 Inventory (IM, IN, and AQ scales).
RESULTS
Pilot study
A total of 66 patients were included in the pilot study. Forty-
five (68%) of them were men. The mean ( standard devia-
tion) age was 37 (9) years with 7 (3) years of HIV infec-
tion. The use of intravenous drugs was the infection route in 27
(41%) patients, 16 (24%) heterosexual contact, 12 (18%) men
who had sex with men and 2 (3%) blood product transfusion.
Nine (14%) patients provided no information about their in-
fection route.
None of the questionnaires presented limitations for correc-
tion. They were completed adequately and the correction pro-
cess of the SERAD was developed as expected. The inter-
viewers did not report aspects not covered in the questionnaire
and no investigators stated that they had encountered any dif-
ficulties collecting the information. The mean time taken to
complete the information was 3.8 (1.8) min at month 1 and
3.3 (1.7) at month 2.
Bland and Altman’s method showed that high agreement lev-
els were found, particularly when adherence percentages were
high. This fact was observed with regard to the comparison be-
tween the SERAD and electronic monitoring, the SERAD and
pill count, and electronic monitoring and pill count. Bland and
Altman’s method for month 1 is shown in Fig. 1. The best lev-
els of agreement were found between the SERAD and elec-
tronic monitoring (75%) and between the SERAD and pill count
(71%). Differences between methods increased when adherence
fell.
After considering the data obtained, the design of the ques-
tionnaire was maintained for its validation in the multicenter
study.
Multicenter study
A total of 489 patients were informed about the purposes and
procedure of the study, and 464 (95%) agreed to participate and
gave their written consent. Sixty-seven percent of the patients
were men, with a mean age of 38 (10) years. The infection
route was intravenous drug use in 33% of patients, 32% het-
erosexual intercourse, 23% men having sex with men, and 5%
blood product transfusion. No information was given by the re-
maining 7%. The mean years of infection were 8 (5). The rest
of demographic, clinical, and psychological information is dis-
played at Table 1.
In the course of the study, 986 SERAD questionnaire forms
were obtained (393, 343, and 250 at months 1, 2, and 3, re-
spectively). The total mean time to complete the SERAD was
3.7 (3.2) min, and mistakes were detected in 2.4% of the to-
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TABLE 1. BASELINE DEMOGRAPHIC AND CLINICAL
CHARACTERISTICS OF STUDY PARTICIPANTSa
Sex (male) 305 (67%)
Age (years) 38 ( 10)
Infection route
Injected drug user 33%
Heterosexual 32%
Homosexual 23%
Blood transfusion 5%
Unknown 7%
Time since HIV diagnosis (years) 8 ( 5)
Number of patients reporting toxic substances consumption 220 (47%)
CD4 cell count (cells/ml) 497 ( 353)
% CD4 cell count (cells/ml) 27 ( 49)
Viral load (log10) 4.3 ( 5)
Time on treatment (weeks) 59 ( 62)
Perceived social support (VAS) 81 ( 31)
Perceived self-efficacy (VAS) 94 ( 13)
Depression (BDI) 11 ( 9)
aData expressed as mean values ( standard deviation), except when specified.
VAS, visual analogue scale; BDI, Beck depression inventory.
tal forms completed. All evaluators considered the question-
naire easy to complete and no significant suggestions to im-
prove it were received.
As far as pill count and electronic monitoring are concerned,
633 (253, 229, 151) and 100 (38, 32, 30) forms were recorded,
respectively. Table 2 shows results from the SERAD and the
pill count at each visit, and Table 3 shows the same measures
regarding electronic monitoring.
To study the comparison between both of the main time set-
tings considered in the study, adherence over the last week and
the last month, a subanalysis was developed with regard to the
comparison between all the study participants assessed by the
SERAD or pill count or electronic monitoring, and the sub-
group of those participants that was electronically monitored.
When last-week and last-month adherence percentages were
compared, the greatest differences in agreement observed be-
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TABLE 2. PERCENTAGES OF ADHERENCE AND INTAKE CONDITIONS OBSERVED, ACCORDING TO THE SERAD AND PILL COUNT
Month Method Period Measure N Mean ( SD) Min–Max
1 SERAD Week Adherence 373 97.7 ( 7.6) 0–100
Intake cond. 372 97.7 ( 9.4) 0–100
Month Adherence 373 94.4 ( 12.4) 0–100
Intake cond. 372 98.3 ( 6.0) 13–100
Pill count Month Adherence 236 91.3 ( 17.5) 0–100
2 SERAD Week Adherence 323 98.2 ( 5.9) 28.6–100
Intake cond. 323 98.3 ( 8.0) 0–100
Month Adherence 323 94.4 ( 11.3) 14.3–100
Intake cond. 323 98.5 ( 6.8) 20.4–100
Pill count Month Adherence 210 88.5 ( 19.5) 0.0–100
3 SERAD Week Adherence 232 98.6 ( 3.9) 74.3–100
Intake cond. 232 98.5 ( 6.5) 28.6–100
Month Adherence 232 96.6 ( 7.1) 60.7–100
Intake cond. 232 99.1 ( 2.8) 73.3–100
Pill count Month Adherence 138 84.7 ( 22.7) 0.0–100
TABLE 3. PERCENTAGES OF ADHERENCE AND INTAKE CONDITIONS OBSERVED, ACCORDING TO THE SERAD, 
ELECTRONIC MONITORING, AND PILL COUNT FOR PATIENTS MONITORED ELECTRONICALLY
Month Method Period Measure N Mean ( SD) Min–Max
1 SERAD Week Adherence 33 93.7 ( 17.8) 0–100
Intake cond. 32 94.3 ( 16.4) 16.6–100
Month Adherence 33 89.6 ( 20.8) 0–100
Intake cond. 32 94.1 ( 16.3) 20–100
EMa Week Adherence 38 89.7 ( 21.8) 0–100
Week Intake cond. 37 85.7 ( 16.9) 35.7–100
Month Adherence 38 91.8 ( 16.7) 4.5–100
Month Intake cond. 38 85.9 ( 15.3) 49.1–100
Pill count Month Adherence 34 93.9 ( 16.5) 3.1–100
2 SERAD Week Adherence 32 98.6 ( 3) 90.5–100
Week Intake cond. 32 96.9 ( 9.1) 50–100
Month Adherence 32 94.9 ( 8.9) 57.1–100
Month Intake cond. 32 99.0 ( 2.3) 88.3–100
EM Week Adherence 32 94.0 ( 11.7) 57.1–100
Week Intake cond. 32 85.7 ( 16.9) 42.9–100
Month Adherence 32 93.0 ( 11.6) 62.2–100
Month Intake cond. 32 85.1 ( 15.6) 40–100
Pill count Month Adherence 26 87.7 ( 21.9) 0–100
3 SERAD Week Adherence 27 97.3 ( 4.5) 85.7–100
Week Intake cond. 27 96.2 ( 10.3) 53.9–100
Month Adherence 27 93.1 ( 11.8) 57.1–100
Month Intake cond. 27 98.3 ( 3.8) 85.2–100
EM Week Adherence 30 93.5 ( 15.1) 21.4–100
Week Intake cond. 30 78.7 ( 24.9) 0–100
Month Adherence 30 94.9 ( 10.5) 46.2–100
Month Intake cond. 30 79.8 ( 17.3) 48.1–100
Pill count Month Adherence 23 90.7 ( 21.1) 0–100
aEM, electronic monitoring.
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tween both measures were 3.7% in all participants and 4.7% in
the subgroup. When only electronic monitoring assessment was
studied, the greatest difference found was 2%. These differ-
ences did not present statistical significance.
Logistic regression analysis determined that none of the vari-
ables considered showed a significant influence between pa-
tients and methods (data not shown). Bland and Altman’s anal-
ysis made it possible to obtain levels of agreement between
different adherence assessment methods, and showed that high
levels were observed, particularly when adherence was high.
Figure 2 shows the agreement between SERAD and pill count.
When only patients electronically monitored were analyzed,
differences between the SERAD and electronic cap bottles mea-
sures were less than 3% comparing adherence in the last month
in all cases. Table 2 shows results from the SERAD, pill count,
and electronic monitoring at each visit for electronically mon-
itored patients. The comparison between the SERAD and pill
count measures made it possible to observe differences obtained
in a range between 0.5% and 6.6%.
When the intake conditions percentage was compared, dif-
ferences increased in a range of 9–17%. Bland and Altman’s
method provided a very similar profile of results for all partic-
ipants.
Differences between the SERAD, electronic monitoring, and
pill count are shown in Table 4.
One hundred and eighty-four samples (40%) were obtained
to determine plasma drug monitoring. Rates of agreement be-
tween this assessment method and the others were very high
(data not shown).
When the last-week adherence percentage of the SERAD was
considered, an agreement was observed in 141 of 166 patients
(85%). When the last-month adherence percentage was con-
sidered it was 119 out of 166 (72%). On the other hand, pill
count coincided with plasma drug levels in only 59 of 100 cases
(59%).
When only patients on electronic monitoring were consid-
ered, the last-week adherence percentage of the SERAD agreed
with plasma drug levels in 11 of 14 cases (78.6%), and in 8 of
14 (57.1%) when the last month was evaluated. In this sub-
group, pill count agreement was found in 8 of 9 cases (88.9%).
Finally, rates of last-week electronic monitoring showed agree-
ment in 11 of 14 cases (73.4%) and in 12 of 15 (80%) for the
last month.
DISCUSSION
The results of this study reveal that the SERAD question-
naire presents an accuracy comparable to other adherence mea-
surement methods; in addition, it is a feasible, reliable, and use-
ful instrument for assessing HAART adherence in HIV-infected
patients.
The feasibility of the SERAD was based particularly on the
time taken to apply the questionnaire. This variable was con-
trolled in each form and it was observed that the SERAD is a
brief and rapid assessment instrument (particularly due to the
3.7 min obtained as the mean of the total time). This advantage
should also be evaluated on the basis of the correct use of the
SERAD shown by participants and evaluators. In this regard,
the application of the questionnaire was also monitored in or-
der to achieve an adequate questionnaire correction process.
There was no questionnaire that could not be corrected, and
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TABLE 4. DIFFERENCES AMONG DIFFERENT ADHERENCE ASSESSMENTS
Month Methoda Period Measure n Mean ( SD) Min–Max
1 EM-SE Week Adherence 32 3.6 ( 11.9) (50)–14.3
Intake cond. 31 9.3 ( 22.4) (60)–66.7
Month Adherence 32 1.8 ( 11.5) (20.5)–54.2
Intake cond. 31 9.6 ( 16.5) (49.2)–31.7
PC-SE Month Adherence 24 4.3 ( 7.55) (7.55)–53
PC-EM Month Adherence 27 0.5 ( 2.5) (3.5)–8.2
2 EM-SE Week Adherence 32 4.6 ( 10.5) (35.7)–7.1
Intake cond. 32 11.2 ( 19.4) (57.2)–36.7
Month Adherence 32 1.8 ( 10.6) (37.8)–12.6
Intake cond. 32 13.8 ( 16) (60)–5
PC-SE Month Adherence 25 6.5 ( 16.3) (57.1)–14.3
PC-EM Month Adherence 25 5.3 ( 16.6) (65.7)–29
3 EM-SE Week Adherence 27 4.1 ( 16.4) (78.6)–14.3
Intake cond. 27 16.7 ( 25.8) (100)–7.7
Month Adherence 27 2.4 ( 8.7) (11)–35.5
Intake cond. 27 17.0 ( 16.7) (48)–1.7
PC-SE Month Adherence 22 3.7 ( 14.8) (57.1)–11.1
PC-EM Month Adherence 23 6.6 ( 20.2) (92.6)–3.9
aEM, electronic monitoring; SE, SERAD; PC, pill count.
FIG. 2. (A) Agreement between pill count and SERAD in last month adherence measure. Month 1 (n  236). (B) Agreement
between pill count and SERAD in last month adherence measure. Month 2 (n  210). (C) Agreement between pill count and
SERAD in last month adherence measure. Month 3 (n  138).
there were no mistakes limiting the obtainment of adherence
measures. In addition, interviewers felt confident using the
questionnaire and confirmed that it could be applied quickly
and easily.
The study of the validity of a questionnaire is not an easy
task. Moreover, patient self-reporting has usually been ques-
tioned, since the information provided may be biased.9 Real
values may be overestimated and reliable data might be diffi-
cult to collect if the responder does not collaborate adequately.
This limitation is obviously not easy to solve. Moreover, when
questions cover a short time, values may not be representative,
and if they cover a longer period of time, forgetfulness may
produce an undesirable effect.21 For this reasons the elabora-
tion of SERAD took these issues into account. Questions for-
mulated within the questionnaire were open and covered three
time settings, the last week, the last month, and the last 3
months, although only the first two were considered in the
study. In this sense, the measure showing the greatest stability
was the last-week adherence value.
Since there is no “gold standard” for comparing methods,
we seek high levels of agreement when studying the outcomes
of the different assessing methods. Consequently, we observed
high levels of agreement between methods, specially when
high levels of adherence existed; in contrast, this agreement
decreased when adherence scores were lower. Probably this
is a bias in the results of the study. Nevertheless, we think
that this is critical for the design study, but not a limitation of
the questionnaire. One reason for finding low validity assess-
ing low levels of adherence may probably be due to the sig-
nificant number of participants who dropped out of the study
within 3 months. Considering this, the association between
low agreement and low adherence may be the result of the re-
lationship between being nonadherent and being more likely
to drop out of care, and thus out of the study. From this point
of view, the most adherent subjects would have been who
would have arrived at the end of the study follow-up. Fur-
thermore, other explanations for this low agreement may be
associated with the effect of overestimation in self-reporting
methods.9 In this sense, it is expected that the patient report
may differ more considerably when more missed doses are re-
ported, as found in other studies. Therefore this limitation
must be clearly taken into consideration, not only for the
SERAD questionnaire, but for all the studies investigating the
adherence to HAART.
Finally, usefulness was assessed in terms of the advantages
presented by the questionnaire. In our opinion, perhaps the
main advantage of the SERAD was the possibility of obtain-
ing different quantitative adherence percentages, providing
nine measures, separated by three time settings (last week, last
month, and last 3 months), and two types of adherence mea-
sures (with regard to the total number of doses prescribed and
the total times that intake conditions are not observed). Sim-
ilarly, an additional characteristic of the SERAD was the em-
phasis on associating inadequate adherence with its reasons.
There is no doubt that it is important to know the reasons for
presenting suboptimal adherence and, in this sense, the
SERAD consequently covers each reason for each kind of in-
adequate behavior. The possibility of assessing intake condi-
tions observed is another advantage of the questionnaire, and
while this percentage does not appear as a resistant measure
in our investigation, this aspect may be addressed more ex-
tensively in further studies.
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